NCT03675685 - Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With EFP | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions

Edematous Fibrosclerotic Panniculopathy

Interventions

BIOLOGICAL

CCH (collagenase clostridium histolyticum)

A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.

Trial Locations (1)

21201

Endo Clinical Trial Site #1, Baltimore